Alymsys (bevacizumab-maly) vs HLX04
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: VEGF-A · full Non-Small Cell Lung Cancer pipeline
Alymsys (bevacizumab-maly)
Marketed by Amneal Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
HLX04 · Hanbeitai
Marketed by Shanghai Henlius Biotech
NCT03952403 · Phase 3 · status unknown
Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The first listed primary outcome for this study is Part 1 safety and tolerability; the survival figures shown here are the Part 2 primary endpoint (progression-free survival) and the overall-survival secondary endpoint from the final analysis.
Reported efficacy
Part 1 Safety and tolerability of study treatment (baseline to 21 days); Part 2-Progression Free Survival (PFS) as Determined by the IRRC using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (Baseline until disease progression or death, whichever occurs first (up to approximately 24months)): ASTRUM-002 met the primary endpoint of progression-free survival with the combination of serplulimab plus HLX04 (bevacizumab biosimilar) and chemotherapy at interim analysis. A total of 636 patients were randomized 1:1:1 to serplulimab plus HLX04 and chemotherapy (group A), serplulimab plus HLX04 placebo and chemotherapy (group B), or double placebo plus chemotherapy (group C). Serplulimab plus chemotherapy significantly prolonged OS and maintained the PFS benefit compared to chemotherapy; however, the addition of the bevacizumab biosimilar HLX04 did not yield further improvement for first-line treatment of nonsquamous NSCLC. (mixed)
Result source: NCT03952403
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Alymsys (bevacizumab-maly) | HLX04 |
|---|---|---|
| PFS, median | 8.3 vs 8.6vs AvastinNCT03296163 | —Not reported |
| OS, median | —Not reported | —Not reported |
| ORR | 40.3% vs 44.6%vs AvastinNCT03296163 | —Not reported |
| Duration of response, median | —Not reported | —Not reported |
PFS, median
- Alymsys (bevacizumab-maly)
- 8.3 vs 8.6vs AvastinNCT03296163
- HLX04
- —Not reported
OS, median
- Alymsys (bevacizumab-maly)
- —Not reported
- HLX04
- —Not reported
ORR
- Alymsys (bevacizumab-maly)
- 40.3% vs 44.6%vs AvastinNCT03296163
- HLX04
- —Not reported
Duration of response, median
- Alymsys (bevacizumab-maly)
- —Not reported
- HLX04
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Alymsys (bevacizumab-maly): 3 of 4 rows · HLX04: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Alymsys (bevacizumab-maly) |
|---|---|
| Dropout rate | 34.3%a NCT03296163 · Phase 3 |
| Discontinued due to AEs | —a NCT03296163 · Phase 3 |
| Serious AEs | 18.6%a NCT03296163 · Phase 3 |
| Most frequent reported AEs |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Alymsys (bevacizumab-maly)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Alymsys (bevacizumab-maly)'s landscape · HLX04's landscape